These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 25554350)

  • 21. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
    Nakamura M; Yamada N; Ito M
    J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of the new oral anticoagulants: opportunities and challenges.
    Yeh CH; Hogg K; Weitz JI
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.
    Zheng SS; Chong JJ; Chong BH
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):575-80. PubMed ID: 26982962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Khemasuwan D; Suramaethakul N
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New anticoagulants for the treatment of venous thromboembolism.
    Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R
    J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive evaluation of apixaban in the treatment of venous thromboembolism.
    Koehl JL; Hayes BD; Al-Samkari H; Rosovsky R
    Expert Rev Hematol; 2020 Feb; 13(2):155-173. PubMed ID: 31958251
    [No Abstract]   [Full Text] [Related]  

  • 32. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
    Lee S; White CM
    Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
    Sato D; Ikeda S; Koga S; Yamagata Y; Eguchi M; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
    Heart Vessels; 2019 Apr; 34(4):678-687. PubMed ID: 30341629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New oral anticoagulants: should they replace heparins and warfarin?
    Tsiara S; Pappas K; Boutsis D; Laffan M
    Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promise of novel direct oral anticoagulants.
    Hoffman R; Brenner B
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):351-60. PubMed ID: 22959551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.